Core Insights - Denny's reported revenue of $117.66 million for the quarter ended June 2025, reflecting a 1.5% increase year-over-year, and an EPS of $0.09, down from $0.13 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $117.5 million by 0.13%, while the EPS fell short of the consensus estimate of $0.10 by 10% [1] Financial Performance - Denny's shares have declined by 20.4% over the past month, contrasting with a 0.6% increase in the Zacks S&P 500 composite [3] - The company operated 84 restaurants at the end of the period, matching the average estimate from two analysts [4] - Same-Restaurant Sales for Company Restaurants remained flat at 0%, compared to an average estimate of -0.3% [4] - Domestic System-wide Restaurants experienced a decline of 1.3% in Same-Restaurant Sales, worse than the estimated decline of 0.8% [4] - Total restaurants at the end of the period numbered 1,558, exceeding the average estimate of 1,548 [4] Revenue Breakdown - Franchise and license revenue was reported at $59.26 million, below the average estimate of $59.93 million, representing a year-over-year decline of 3.8% [4] - Company restaurant sales reached $58.4 million, surpassing the average estimate of $57.58 million, with a year-over-year increase of 7.5% [4] Operating Margins - Franchise Operating Margin was reported at $30.05 million, slightly below the average estimate of $30.58 million [4] - Company Restaurant Operating Margin stood at $6.05 million, compared to the average estimate of $6.44 million [4]

MercadoLibre (MELI) reported $6.79 billion in revenue for the quarter ended June 2025, representing a year- over-year increase of 33.9%. EPS of $10.31 for the same period compares to $10.48 a year ago. Here is how MercadoLibre performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: View all Key Company Metrics for MercadoLibre here>>> Shares of MercadoLibre have returned -5.5% over the past month versus the Zacks S&P 500 composite's +0.6% c ...

Core Insights - Mettler-Toledo reported revenue of $983.22 million for the quarter ended June 2025, marking a year-over-year increase of 3.9% and exceeding the Zacks Consensus Estimate of $957.64 million by 2.67% [1] - The company's EPS for the same period was $10.09, up from $9.65 a year ago, representing a surprise of 5.32% compared to the consensus estimate of $9.58 [1] Revenue Breakdown - Net Sales- Products reached $734.24 million, surpassing the average estimate of $726.47 million, with a year-over-year change of +3.1% [4] - Net Sales- Service totaled $248.98 million, exceeding the average estimate of $229.94 million, reflecting a year-over-year increase of +6.2% [4] - Net Sales- Retail amounted to $50.68 million, above the average estimate of $47.83 million, with a year-over-year change of +2.9% [4] - Net Sales- Industrial was reported at $394.63 million, compared to the average estimate of $384.01 million, indicating a year-over-year increase of +5.4% [4] - Net Sales- Laboratory reached $537.92 million, exceeding the average estimate of $529.1 million, with a year-over-year change of +2.8% [4] Stock Performance - Mettler-Toledo shares have returned +2% over the past month, slightly underperforming the Zacks S&P 500 composite's +2.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Viewpoint - The financial performance of Daodaquan (002852) for the first half of 2025 shows significant growth in net profit and profitability metrics, indicating a positive trend in the company's operations and financial health [1]. Financial Performance Summary - Total revenue for the first half of 2025 reached 2.792 billion yuan, a year-on-year increase of 1.16% [1]. - Net profit attributable to shareholders was 181 million yuan, reflecting a substantial year-on-year increase of 563.15% [1]. - The gross profit margin improved to 11.65%, up 24.85% year-on-year, while the net profit margin surged to 6.64%, an increase of 612.48% [1]. - The total of selling, administrative, and financial expenses was 109 million yuan, accounting for 3.9% of revenue, down 43.32% year-on-year [1]. - Earnings per share (EPS) rose to 0.53 yuan, a remarkable increase of 562.5% compared to the previous year [1]. Cash Flow and Asset Management - Operating cash flow per share decreased to 0.94 yuan, down 76.48% year-on-year, indicating increased payments for goods [1]. - The company experienced a significant decrease in cash and cash equivalents, with a net increase of -266.65% due to higher payments for goods [3]. - The company’s monetary funds decreased by 63.83% due to increased raw material procurement costs [3]. Liabilities and Financial Health - Interest-bearing liabilities decreased by 39.12% to 1.143 billion yuan, suggesting improved debt management [1]. - The company’s total liabilities and asset management metrics indicate a need for careful monitoring, with a current ratio of monetary funds to current liabilities at only 12.07% [4]. Investment and Market Position - The company’s return on invested capital (ROIC) was reported at 6.82%, with historical performance showing variability and a median ROIC of 10.71% since its listing [4]. - Analysts project the company's performance for 2025 to reach a net profit of 223 million yuan, with an average EPS forecast of 0.65 yuan [4]. Fund Holdings - The largest fund holding Daodaquan shares is the Rongtong Tongqian Research Selected Flexible Allocation Mixed A fund, which has recently entered the top ten holdings [5].

Core Insights - Franklin Resources reported $2.06 billion in revenue for the quarter ended June 2025, a year-over-year decline of 2.8%, with EPS of $0.49 compared to $0.60 a year ago, exceeding the Zacks Consensus Estimate of $2 billion by 3.4% [1] - The company delivered an EPS surprise of 2.08%, with the consensus EPS estimate being $0.48 [1] Financial Performance - Total Net Flows were reported at $-6.60 billion, better than the three-analyst average estimate of $-12.88 billion [4] - Assets Under Management (AUM) totaled $1,611.80 billion, exceeding the three-analyst average estimate of $1,588.40 billion [4] - AUM in Fixed Income was $441.70 billion, below the estimate of $452.27 billion; Multi-Asset AUM was $183.20 billion, above the estimate of $175.25 billion; Equity AUM was $656.60 billion, above the estimate of $639.18 billion; Alternative AUM was $258.40 billion, above the estimate of $250.18 billion; Cash Management AUM was $71.90 billion, slightly above the estimate of $71.51 billion [4] Revenue Breakdown - Operating Revenues from Investment Management Fees were $1.64 billion, exceeding the average estimate of $1.56 billion, representing a year-over-year change of -2.9% [4] - Operating Revenues from Shareholder Servicing Fees were $59.9 million, compared to the estimated $58.57 million, reflecting a -3.1% change year-over-year [4] - Operating Revenues from Sales and Distribution Fees were $351.9 million, exceeding the three-analyst average estimate of $344.14 million, with a year-over-year change of -1.8% [4] Stock Performance - Shares of Franklin Resources returned -3.5% over the past month, while the Zacks S&P 500 composite increased by 2.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

For the quarter ended June 2025, Reddit Inc. (RDDT) reported revenue of $499.63 million, up 77.7% over the same period last year. EPS came in at $0.45, compared to -$0.06 in the year-ago quarter. Shares of Reddit Inc. have returned -6.3% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. The reported revenue compares to the Zacks Consensus Estimate of $427.41 ...

Core Insights - Allegheny Technologies (ATI) reported revenue of $1.14 billion for the quarter ended June 2025, reflecting a 4.1% increase year-over-year, with EPS at $0.74 compared to $0.60 in the same quarter last year [1] - The reported revenue matched the Zacks Consensus Estimate, but the EPS exceeded expectations by 2.78% [1] Financial Performance - High Performance Materials & Components sales were $608.8 million, which was below the estimated $621.48 million, but showed an 8.3% increase from the previous year [4] - Advanced Alloys & Solutions sales reached $531.6 million, slightly above the estimated $525.28 million, but represented a year-over-year decline of 0.3% [4] - EBITDA for Advanced Alloys & Solutions was $76.7 million, below the average estimate of $78.22 million, while EBITDA for High Performance Materials & Components was $144 million, exceeding the estimate of $140.02 million [4] Stock Performance - Shares of Allegheny Technologies have increased by 10.1% over the past month, outperforming the Zacks S&P 500 composite, which rose by 2.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Here is how CVS Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: View all Key Company Metrics for CVS Health here>>> Shares of CVS Health have returned -6.5% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Medical benefit ratio (MBR): 89.9% versus the seven-analyst average estimate of 9 ...

Core Insights - Apellis Pharmaceuticals, Inc. reported a revenue of $178.49 million for the quarter ended June 2025, reflecting a year-over-year decline of 10.6% [1] - The earnings per share (EPS) for the same period was -$0.33, compared to -$0.28 a year ago, with a consensus EPS estimate of -$0.44, resulting in a surprise of +25% [1] Revenue Breakdown - Product revenue, net was $171.39 million, below the 10-analyst average estimate of $176.3 million, representing a year-over-year change of -4.3% [4] - Licensing and other revenue amounted to $7.11 million, significantly lower than the 10-analyst average estimate of $12.89 million, showing a year-over-year decline of 65.4% [4] - Product revenue from EMPAVELI was $20.8 million, compared to the seven-analyst average estimate of $21.74 million, indicating a year-over-year change of -15.1% [4] - Product revenue from SYFOVRE was $150.6 million, slightly below the seven-analyst average estimate of $153.77 million, with a year-over-year change of -2.6% [4] Stock Performance - Shares of Apellis Pharmaceuticals have returned +6.6% over the past month, outperforming the Zacks S&P 500 composite's +2.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Performance - Sleep Number reported revenue of $327.93 million for the quarter ended June 2025, reflecting a year-over-year decline of 19.7% [1] - The EPS for the same period was -$1.09, compared to -$0.22 a year ago, indicating a significant deterioration in profitability [1] - The reported revenue was an 8.97% miss compared to the Zacks Consensus Estimate of $360.25 million [1] - The EPS surprise was -808.33% against the consensus estimate of -$0.12 [1] Market Performance - Sleep Number's shares have returned +15.9% over the past month, outperforming the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3] Store Metrics - The number of stores at the end of the period was 630, compared to an average estimate of 638 by two analysts [4] - Total company sales change rate was -20%, significantly worse than the -8.7% estimated by two analysts [4] - The number of stores at the beginning of the period remained unchanged at 637, matching the average estimate [4]